WO2005123679A2 - Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - Google Patents

Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors Download PDF

Info

Publication number
WO2005123679A2
WO2005123679A2 PCT/EP2005/052731 EP2005052731W WO2005123679A2 WO 2005123679 A2 WO2005123679 A2 WO 2005123679A2 EP 2005052731 W EP2005052731 W EP 2005052731W WO 2005123679 A2 WO2005123679 A2 WO 2005123679A2
Authority
WO
WIPO (PCT)
Prior art keywords
tetramethyl
piperidine
phenoxy
disorder
chloro
Prior art date
Application number
PCT/EP2005/052731
Other languages
French (fr)
Other versions
WO2005123679A3 (en
Inventor
Dan Peters
Gunnar M. Olsen
Elsebet Østergaard NIELSEN
Jørgen SCHEEL-KRÜGER
Birgitte L. Eriksen
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Priority to JP2007515944A priority Critical patent/JP2008502651A/en
Priority to EP05761133A priority patent/EP1761493A2/en
Priority to CA002570075A priority patent/CA2570075A1/en
Priority to US11/579,060 priority patent/US7547788B2/en
Priority to MXPA06013917A priority patent/MXPA06013917A/en
Publication of WO2005123679A2 publication Critical patent/WO2005123679A2/en
Publication of WO2005123679A3 publication Critical patent/WO2005123679A3/en
Priority to US12/437,233 priority patent/US7915419B2/en
Priority to US12/970,274 priority patent/US20110086880A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Definitions

  • This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors.
  • the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
  • WO 97/30997 describes tropane derivatives active as neurotransmitter re-uptake inhibitors.
  • an optimised pharmacological profile as regards the activity on reuptake of the monoamine neurotransmitters serotonin, dopamine and noradrenaline, such as the ratio of the serotonin reuptake versus the noradrenaline and dopamine reuptake activity.
  • Morishima et al [Morishima Y, Fujita J, Ikeda T & Kamachi M; Chemistry Letters
  • the invention provides a piperidine derivative of the Formula I:
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides the use of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
  • the invention relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
  • R a represents hydrogen or alkyl; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl;
  • R a represents hydrogen or alkyl. In a special embodiment, R a represents hydrogen. In a further embodiment, R a represents alkyl, such as methyl. In a still further embodiment, R a represents alkyl substituted with cyano, such as cyanomethyl. In a still further embodiment, R b represents an optionally substituted phenyl. In a further embodiment, R b represents a phenyl group, which phenyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy.
  • R b represents a phenyl group, which phenyl group is optionally substituted twice with halo.
  • R b represents dichloro-phenyl, such as 3,4-dichloro-phenyl, 2,4-dichloro-phenyl or 2,5-dichloro- phenyl.
  • R b represents bromo-chloro-phenyl, such as 4- bromo-3-chloro-phenyl or 3-bromo-4-chloro-phenyl.
  • R b represents chloro-fluoro-phenyl, such as 3-chloro-4-fluoro-phenyl, 4-chloro-3-fluoro- phenyl, 2-chloro-5-fluoro-phenyl or 4-chloro-2-fluoro-phenyl.
  • R b represents a tri-halo-phenyl.
  • R b represents trichloro-phenyl, such as 2,4,5-trichlorophenyl, 2,3,4- trichlorophenyl or 2,3,5-trichlorophenyl.
  • R b represents bromo-difluoro-phenyl, such as 4-bromo-2,3-difluorophenyl.
  • R represents a halo-phenyl.
  • R ⁇ b represents chlorophenyl, such as 4-chloro-phenyl.
  • R b represents a trifluoromethyl-phenyl, such as 4- trifluoromethyl-phenyl.
  • R b represents a halo-trifluoro- methyl-phenyl, such as chloro-trifluoromethyl-phenyl, such as 4-chloro-3-trifluoro- methyl-phenyl.
  • R b represents a halo-alkoxy-phenyl, such as chloro-methoxy-phenyl, such as 4-chloro-3-methoxy-phenyl.
  • R b represents a dihalo-alkoxy-phenyl, such as bromo-chloro-methoxy- phenyl, such as 2-bromo-4-chloro-5-methoxy-phenyl.
  • R b represents a dialkoxy-phenyl, such as dimethoxy-phenyl, such as 2,3-dimethoxy- phenyl.
  • R represents an optionally substituted naphthyl.
  • R b represents naphthyl, such as naphthalen-1-yl.
  • X represents -O-.
  • X represents -NR C -.
  • R c represents hydrogen.
  • R c represents alkyl, such as methyl.
  • R 2 , R 2 , R 6 and R 6 represent alkyl, such as methyl; and R 3 , R 3' , R 5 and R 5' represent hydrogen.
  • halo represents fluoro, chloro, bromo or iodo.
  • an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain.
  • the hydrocarbon chain preferably contains of from one to six carbon atoms (C 1-6 -alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl.
  • alkyl represents a C1.
  • - alkyl group including butyl, isobutyl, secondary butyl, and tertiary butyl.
  • alkyl represents a C ⁇ -3-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
  • an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes.
  • the alkenyl group of the invention comprises of from two to six carbon atoms (C 2-6 -alkenyl), including at least one double bond.
  • the alkenyl group of the invention is ethenyl; 1- or 2-propenyl; 1-, 2- or 3- butenyl, or 1 ,3-butadienyl; 1-, 2-, 3-, 4- or 5-hexenyl, or 1 ,3-hexadienyl, or 1 ,3,5- hexatrienyl.
  • an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes.
  • the alkynyl group of the invention comprises of from two to six carbon atoms (C 2-6 -alkynyl), including at least one triple bond.
  • the alkynyl group of the invention is ethynyl; 1-, or 2-propynyl; 1-, 2-, or 3-butynyl, or 1 ,3-butadiynyl; 1-, 2-, 3-, 4-pentynyl, or 1,3-pentadiynyl; 1-, 2-, 3-, 4-, or 5-hexynyl, or 1 ,3-hexadiynyl or 1,3,5-hexatriynyl.
  • a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C ⁇ -cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Alkoxy is O-alkyl, wherein alkyl is as defined above.
  • Cycloalkoxy means O-cycloalkyl, wherein cycloalkyl is as defined above.
  • Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl.
  • Amino is NH 2 or NH-alkyl or N-(alkyl) 2 , wherein alkyl is as defined above.
  • an aryl group designates a carbocyclic aromatic ring system such as phenyl, naphthyl (1 -naphthyl or 2-naphthyl) orfluorenyl.
  • the chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
  • pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnam
  • Such salts may be formed by procedures well known and described in the art.
  • Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
  • pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysine, and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group.
  • Such cationic salts may be formed by procedures well known and described in the art.
  • onium salts of N-containing compounds are also contemplated as pharmaceutically acceptable salts.
  • Preferred “onium salts” include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
  • Examples of pre- or prodrug forms of the chemical compound of the invention include examples of suitable prodrugs of the substances according to the invention include compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.
  • the chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like.
  • Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • the compounds of the present invention may contain one or more chiral centers, and that such compounds exist in the form of isomers.
  • the compounds of the present invention may exist in cis or trans configurations as well as in mixtures thereof.
  • those of the substituents R 2 /R 2 , R 3 /R 3 , R 5 /R 5 , and R 6 /R 6 which represent alkyl may in particular be in cis or trans configuration relative to each another (e.g. R 2 relative to R 5 , or R 3 relative to R 5 ).
  • the invention includes all such isomers and any mixtures thereof including racemic mixtures.
  • the chemical compounds of the present invention may exist as enantiomers in (+) and (-) forms as well as in racemic forms ( ⁇ ).
  • the racemates of these isomers and the individual isomers themselves are within the scope of the present invention.
  • the invention includes all such isomers and any mixtures thereof including racemic mixtures. Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the isomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix.
  • Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example.
  • the chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like. Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by Jaques J, Collet A, & Wilen S in
  • Optical active compounds can also be prepared from optical active starting materials.
  • the compounds of the invention may be used in their labelled or unlabelled form.
  • the labelled compound has one or more atoms replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • the labelling will allow easy quantitative detection of said compound.
  • the labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo receptor imaging.
  • the labelled isomer of the invention preferably contains at least one radio- nuclide as a label. Positron emitting radionuclides are all candidates for usage.
  • the radionudide is preferably selected from 2 H (deuterium), 3 H (tritium), 13 C, 14 C, 131 I, 125 I, 123 I, and 18 F.
  • the physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon Imaging Computed Tomography (SPECT), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and Computed Axial X-ray Tomography (CAT), or combinations thereof.
  • the chemical compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention can be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • Biological Activity Compounds of the invention may be tested for their ability to inhibit reuptake of the monoamines dopamine, noradrenaline and serotonin in synaptosomes e.g. such as described in WO 97/30997. Based on the balanced activity observed in these tests the compound of the invention is considered useful for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mamma ⁇ including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of: mood disorder, depression, atypical depression, depression secondary to pain, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, post-traumatic stress disorder, acute stress disorder, drug addiction, drug abuse, cocaine abuse, nicotine abuse, tobacco abuse, alcohol addiction, alcoholism, pain
  • the compounds are considered useful for the treatment, prevention or alleviation of depression.
  • a suitable dosage of the active pharmaceutical ingredient (API) is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • Preferred compounds of the invention show a biological activity in the sub- micromolar and micromolar range, i.e. of from below 1 to about 100 ⁇ M.
  • compositions comprising a therapeutically effective amount of the chemical compound of the invention.
  • a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the chemical compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art.
  • compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, pulmonal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injedion or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.
  • sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.
  • the chemical compound of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof.
  • Such forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the chemical compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the adive component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glyceride or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
  • Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the chemical compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injedion or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • a suitable vehicle e.g. sterile, pyrogen-free water
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations intended for conversion shortly before use to liquid form preparations for oral administration.
  • Such liquid forms include solutions, suspensions, and emulsions.
  • such preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the chemical compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • Compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia ortragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the compositions may be provided in single or multi-dose form.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • the powder carrier will.form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • compositions adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences ( Maack Publishing Co., Easton, PA). A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity, e.g.
  • ED 50 and LD 50 may be determined by standard pharmacological procedures in cell cultures or experimental animals.
  • the dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD 50 /ED 5 o.
  • Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.
  • the dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • the actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect.
  • compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg
  • the active ingredient may be administered in one or several doses per day.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 ⁇ g/kg i.v. and 1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg/day i.v., and from about 1 ⁇ g/kg to about 100 mg/kg/day p.o.
  • the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a chemical compound of the invention.
  • suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • EXAMPLES The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Description

NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS
TECHNICAL FIELD
This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
BACKGROUND ART
WO 97/30997 (NeuroSearch A/S) describes tropane derivatives active as neurotransmitter re-uptake inhibitors. However, there is still a strong need for compounds with an optimised pharmacological profile as regards the activity on reuptake of the monoamine neurotransmitters serotonin, dopamine and noradrenaline, such as the ratio of the serotonin reuptake versus the noradrenaline and dopamine reuptake activity. Morishima et al [Morishima Y, Fujita J, Ikeda T & Kamachi M; Chemistry Letters
1994 3 557-60] describe the synthesis and copolymerization of a mesogenic acrylate. The two compounds 4-(4-hydroxy-phenoxy)-2,2,6,6-tetramethyl-piperidine and 4-(4- methoxy-phenoxy^^.β.β-tetramethyl-piperidine are disclosed; however no pharmaceutical use of these two compounds are disclosed.
SUMMARY OF THE INVENTION
In its first aspect, the invention provides a piperidine derivative of the Formula I:
Figure imgf000002_0001
any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, X, R2, R2, R3, R3, R5, R5, R6 and R6 are as defined below. In its second aspect, the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent. In a further aspect, the invention provides the use of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system. In a still further aspect, the invention relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof. Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.
DETAILED DISCLOSURE OF THE INVENTION
Alkyl substituted piperidine derivatives
In its first aspect the present invention provides piperidine derivatives of formula I:
Figure imgf000003_0001
any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, wherein Ra represents hydrogen or alkyl; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl;
X represents -O-, -S- or -NR°-; wherein Rc represents hydrogen, alkyl, -C(=O)Rd or-SO2Rd; wherein Rd represents hydrogen or alkyl; Rb represents an aryl group, which aryl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; each of R2, R2', R3, R3', R5, R5', R6 and R6' independently of each other represents hydrogen or alkyl; with the proviso that at least one of R2, R2', R3, R3', R5, R5', R6 and R6' represents alkyl; and with the proviso that the compound is not 4-(4-hydroxy-phenoxy)-2,2,6,6-tetramethyl-piperidine or 4-(4-methoxy-phenoxy)-2,2,6,6-tetramethyl-piperidine.
In one embodiment, Ra represents hydrogen or alkyl. In a special embodiment, Ra represents hydrogen. In a further embodiment, Ra represents alkyl, such as methyl. In a still further embodiment, Ra represents alkyl substituted with cyano, such as cyanomethyl. In a still further embodiment, Rb represents an optionally substituted phenyl. In a further embodiment, Rb represents a phenyl group, which phenyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy. In a still further embodiment, Rb represents a phenyl group, which phenyl group is optionally substituted twice with halo. In a special embodiment, Rb represents dichloro-phenyl, such as 3,4-dichloro-phenyl, 2,4-dichloro-phenyl or 2,5-dichloro- phenyl. In a further embodiment, Rb represents bromo-chloro-phenyl, such as 4- bromo-3-chloro-phenyl or 3-bromo-4-chloro-phenyl. In a still further embodiment, Rb represents chloro-fluoro-phenyl, such as 3-chloro-4-fluoro-phenyl, 4-chloro-3-fluoro- phenyl, 2-chloro-5-fluoro-phenyl or 4-chloro-2-fluoro-phenyl. In a further embodiment, Rb represents a tri-halo-phenyl. In a special embodiment, Rb represents trichloro-phenyl, such as 2,4,5-trichlorophenyl, 2,3,4- trichlorophenyl or 2,3,5-trichlorophenyl. In a further embodiment, Rb represents bromo-difluoro-phenyl, such as 4-bromo-2,3-difluorophenyl. In a still further embodiment, R represents a halo-phenyl. In a special embodiment, R ϊb represents chlorophenyl, such as 4-chloro-phenyl. In a further embodiment, Rb represents a trifluoromethyl-phenyl, such as 4- trifluoromethyl-phenyl. In a still further embodiment, Rb represents a halo-trifluoro- methyl-phenyl, such as chloro-trifluoromethyl-phenyl, such as 4-chloro-3-trifluoro- methyl-phenyl. In a further embodiment, Rb represents a halo-alkoxy-phenyl, such as chloro-methoxy-phenyl, such as 4-chloro-3-methoxy-phenyl. In a still further embodiment, Rb represents a dihalo-alkoxy-phenyl, such as bromo-chloro-methoxy- phenyl, such as 2-bromo-4-chloro-5-methoxy-phenyl. In a further embodiment, Rb represents a dialkoxy-phenyl, such as dimethoxy-phenyl, such as 2,3-dimethoxy- phenyl. In a still further embodiment, R represents an optionally substituted naphthyl. In a special embodiment, Rb represents naphthyl, such as naphthalen-1-yl. In a further embodiment, X represents -O-. In a still further embodiment, X represents -NRC-. In a special embodiment, Rc represents hydrogen. In a further embodiment, Rc represents alkyl, such as methyl. In a further embodiment, four of R2, R2', R3, R3', R5, R5', R6 and R6' represent alkyl; and the remaining four of R2, R2', R3, R3', R5, R5', R6 and R6' represent hydrogen. In a special embodiment, R2, R2 , R6 and R6 represent alkyl, such as methyl; and R3, R3', R5 and R5' represent hydrogen.
In a special embodiment the chemical compound of the invention is
4-(3,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(4-Chloro-3-trifluoromethyl-phenoxy)-1,2,2,6,6-pentamethyl-piperidine; 4-(4-Chloro-3-fluoro-phenoxy)-1,2,2,6,6-pentamethyl-piperidine;
4-(4-Bromo-3-chlorophenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(3,4-Dichloro-phenoxy)-1,2,2,6,6-pentamethyl-piperidine;
4-(3-Chloro-4-fluoro-phenoxy)-1,2,2,6,6-pentamethyl-piperidine;
4-(3-Chloro-4-fluoro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(2-Chloro-5-fluoro-phenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(4-Trifluoromethyl-phenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(4-Chloro-phenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(2,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(2,5-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(2,4,5-Trichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(3-Bromo-4-chloro-phenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(2,3,4-TrichIoro-phenoxy)-2,2,6,6-tetramethyl-piperidine;
4-(1-Naphthyloxy)-2,2,6,6-tetramethyl-piperidine;
(3,4-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (4-Chloro-3-trifluoromethylphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine;
(3-Chloro-4-fluorophenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine;
(2-Chloro-5-fluorophenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine;
(4-Chloro-3-methoxyphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (2,4-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine;
(2,5-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine;
(2,3,5-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine;
(2,3-Dimethoxy-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine;
(1-Naphthoxy-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; [4-(3,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidin-1-yl]-acetonitrile;
4-(4-Chloro-3-trifluoromethyl-phenoxy)-2,2,6,6-tetramethyl-piperidine;
(3,4-Dichloro-phenyl)-methyl-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-amine;
(4-Bromo-2,3-fluoro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine;
(4-Chloro-2-fluoro-phenyl)-(2,2,6,6-tetramethyl-piperidin- -yl)-amine; (2-Bromo-4-chloro-5-methoxyphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; or a pharmaceutically acceptable salt thereof.
Any combination of two or more of the embodiments as described above is considered within the scope of the present invention.
Definition of Substituents In the context of this invention halo represents fluoro, chloro, bromo or iodo. In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contains of from one to six carbon atoms (C1-6-alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a C1. - alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In another preferred embodiment of this invention alkyl represents a Cι-3-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl. In the context of this invention an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a preferred embodiment the alkenyl group of the invention comprises of from two to six carbon atoms (C2-6-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1- or 2-propenyl; 1-, 2- or 3- butenyl, or 1 ,3-butadienyl; 1-, 2-, 3-, 4- or 5-hexenyl, or 1 ,3-hexadienyl, or 1 ,3,5- hexatrienyl. In the context of this invention an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes. In a preferred embodiment the alkynyl group of the invention comprises of from two to six carbon atoms (C2-6-alkynyl), including at least one triple bond. In its most preferred embodiment the alkynyl group of the invention is ethynyl; 1-, or 2-propynyl; 1-, 2-, or 3-butynyl, or 1 ,3-butadiynyl; 1-, 2-, 3-, 4-pentynyl, or 1,3-pentadiynyl; 1-, 2-, 3-, 4-, or 5-hexynyl, or 1 ,3-hexadiynyl or 1,3,5-hexatriynyl. In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C^-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Alkoxy is O-alkyl, wherein alkyl is as defined above. Cycloalkoxy means O-cycloalkyl, wherein cycloalkyl is as defined above. Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl. Amino is NH2 or NH-alkyl or N-(alkyl)2, wherein alkyl is as defined above. In the context of this invention an aryl group designates a carbocyclic aromatic ring system such as phenyl, naphthyl (1 -naphthyl or 2-naphthyl) orfluorenyl.
Pharmaceutically Acceptable Salts The chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention. Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulphonate derived from methane sulphonic acid, the naphthalene-2-sulphonate derived from naphtalene-2-sulphonic acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, the sorbate derived from sorbic acid, the stearate derived from stearic acid, the succinate derived from succinic acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulphonic acid, and the like. Such salts may be formed by procedures well known and described in the art. Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt. Examples of pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysine, and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group. Such cationic salts may be formed by procedures well known and described in the art. In the context of this invention the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts. Preferred "onium salts" include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts. Examples of pre- or prodrug forms of the chemical compound of the invention include examples of suitable prodrugs of the substances according to the invention include compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides. The chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
Steric Isomers It will be appreciated by those skilled in the art that the compounds of the present invention may contain one or more chiral centers, and that such compounds exist in the form of isomers. For example, the compounds of the present invention may exist in cis or trans configurations as well as in mixtures thereof. E.g. those of the substituents R2/R2, R3/R3 , R5/R5 , and R6/R6 which represent alkyl may in particular be in cis or trans configuration relative to each another (e.g. R2 relative to R5, or R3 relative to R5). The invention includes all such isomers and any mixtures thereof including racemic mixtures. Moreover, the chemical compounds of the present invention may exist as enantiomers in (+) and (-) forms as well as in racemic forms (±). The racemates of these isomers and the individual isomers themselves are within the scope of the present invention. The invention includes all such isomers and any mixtures thereof including racemic mixtures. Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the isomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example. The chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like. Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by Jaques J, Collet A, & Wilen S in
"Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981). Optical active compounds can also be prepared from optical active starting materials.
Labelled Compounds The compounds of the invention may be used in their labelled or unlabelled form. In the context of this invention the labelled compound has one or more atoms replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. The labelling will allow easy quantitative detection of said compound. The labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo receptor imaging. The labelled isomer of the invention preferably contains at least one radio- nuclide as a label. Positron emitting radionuclides are all candidates for usage. In the context of this invention the radionudide is preferably selected from 2H (deuterium), 3H (tritium), 13C, 14C, 131I, 125I, 123I, and 18F. The physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon Imaging Computed Tomography (SPECT), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and Computed Axial X-ray Tomography (CAT), or combinations thereof.
Methods of Preparation The chemical compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals. Also one compound of the invention can be converted to another compound of the invention using conventional methods. The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
Biological Activity Compounds of the invention may be tested for their ability to inhibit reuptake of the monoamines dopamine, noradrenaline and serotonin in synaptosomes e.g. such as described in WO 97/30997. Based on the balanced activity observed in these tests the compound of the invention is considered useful for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mamma^ including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system. In a special embodiment, the compounds of the invention are considered useful for the treatment, prevention or alleviation of: mood disorder, depression, atypical depression, depression secondary to pain, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, post-traumatic stress disorder, acute stress disorder, drug addiction, drug abuse, cocaine abuse, nicotine abuse, tobacco abuse, alcohol addiction, alcoholism, pain, chronic pain, inflammatory pain, neuropathic pain, migraine pain, tension-type headache, chronic tension-type headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, post-operative pain, post-mastectomy pain syndrome (PMPS), post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically-maintained pain, trigeminal neuralgia, dental pain, myofacial pain, phantom-limb pain, bulimia, premenstrual syndrome, late luteal phase syndrome, post- traumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress incontinence, urge incontinence, nocturnal incontinence, sexual dysfunction, premature ejaculation, erectile difficulty, erectile dysfunction, premature female orgasm, restless leg syndrome, eating disorders, anorexia nervosa, sleep disorders, autism, mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain damage, stroke-induced neuronal damage or Gilles de la Tourettes disease. In a preferred embodiment, the compounds are considered useful for the treatment, prevention or alleviation of depression. It is at present contemplated that a suitable dosage of the active pharmaceutical ingredient (API) is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge. Preferred compounds of the invention show a biological activity in the sub- micromolar and micromolar range, i.e. of from below 1 to about 100 μM.
Pharmaceutical Compositions In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the chemical compound of the invention. While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries. In a preferred embodiment, the invention provides pharmaceutical compositions comprising the chemical compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art. The carriers) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof. Pharmaceutical compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, pulmonal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injedion or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems. Suitable examples of sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules. The chemical compound of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof. Such forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The chemical compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention. For preparing pharmaceutical compositions from a chemical compound of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the adive component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration. For preparing suppositories, a low melting wax, such as a mixture of fatty acid glyceride or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify. Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution. The chemical compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injedion or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents. Also included are solid form preparations, intended for conversion shortly before use to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. In addition to the active component such preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. For topical administration to the epidermis the chemical compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia ortragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form. Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve. Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
Conveniently the powder carrier will.form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler. In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, compositions adapted to give sustained release of the active ingredient may be employed. The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences ( Maack Publishing Co., Easton, PA). A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity, e.g. ED50 and LD50, may be determined by standard pharmacological procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD50/ED5o. Pharmaceutical compositions exhibiting large therapeutic indexes are preferred. The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner. The actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments. The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 μg/kg i.v. and 1 μg/kg p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 μg/kg to about 10 mg/kg/day i.v., and from about 1 μg/kg to about 100 mg/kg/day p.o.
Methods of Therapy In another aspect the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a chemical compound of the invention. It is at present contemplated that suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge. EXAMPLES The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.
General: All reactions involving air sensitive reagents or intermediates were performed under nitrogen and in anhydrous solvents. Magnesium sulphate was used as drying agent in the workup-procedures and solvents were evaporated under reduced pressure.
Method A
4-(3,4-DichIoro-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt A mixture of triphenylphosphine (3.67 g, 14 mmol), dioxane (30 ml), diethylazodi- carboxylate (2.2 ml, 14 mmol), 4-(2,2,6,6-tetramethyl)-piperidinol (1.90 g 12 mmol) and 3,4-dichlorophenol (2.3 g, 14 mmol) was stirred at room-temperature for 15 h. The mixture was evaporated, water (10 ml) and sodium hydroxide (4 ml, 4 M) was added and the mixture was extracted with (3 x 20 ml) diethyl ether. The organic phase was washed with water and was evaporated. The corresponding hydrochloric acid salt was precipitated by addition of hydrochloric acid in ethanol. The mixture was evaporated and the crystals were triturated and stirred in diethyl ether for 15 h. The product was isolated by filtration. Yield 40 mg (1 %).
4-(4-Chloro-3-trifluoromethyl-phenoxy)-1,2,2,6,6-pentamethyl-piperidine hydrochloric acid salt
Was prepared according to method A from 1,2,2,6,6-pentamethyl-piperidin-4-ol and 4- chloro-3-trifluoromethyIphenol. Mp 240-245°C.
4-(4-Chloro-3-fluoro-phenoxy)-1,2,2,6,6-pentamethyl-piperidine hydrochloric acid salt
Was prepared according to method A from 1 ,2,2,6,6-pentamethyl-piperidin-4-ol and 4- chloro-3-fluorophenol. Mp 187.2-190.7°C.
Method B
4-(3,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt
A mixture of 4-(2,2,6,6-tetramethyl)-piperidinol (3.15 g 20 mmol), tetrahydrofuran (50 ml), potassium fe/f-butoxide (6.72 g, 60 mmol) and 1 ,2-dichloro-4-fluorobenzene (2.47 ml, 21 mmol) was stirred for 4 h at room-temperature. Water (100 ml) was added and the mixture was extracted with diethyl ether (2 x 50 ml). Hydrochloric acid in ether (6.5 ml, 3.1 M) was added and the hydrochloric acid salt was precipitated and stirred for 10 min, followed by filtration. Yield 5.69 g (84 %). Mp 291 °C.
4-(4-Bromo-3-chlorophenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt
Was prepared according to method B. Mp 277°C.
4-(3,4-Dichloro-phenoxy)-1,2,2,6,6-pentamethyl-piperidine hydrochloric acid salt Was prepared according to method B from 1 ,2,2,6,6-pentamethyl-piperidin-4-ol. Mp 189.6-195.6°C.
4-(3-Chloro-4-fluoro-phenoxy)-1 ,2,2,6,6-pentamethyl-piperidine hydrochloric acid salt Was prepared according to method B from 1 ,2,2,6,6-pentamethyl-piperidin-4-ol and 1- chloro-2,5-difluorobenzene. Mp 198.0-200.9°C.
4-(3-Chloro-4-fluoro-phenoxy)-2,2,6,6-tetramethyl-piperidϊne hydrochloric acid salt Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 1- chloro-2,5-difluorobenzene. Mp >250°C.
4-(2-Chloro-5-fluoro-phenoxy)-2,2,6,6-tetramethyI-piperidine hydrochloric acid salt Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 1- chloro-2,4-difluorobenzene. Mp >300°C.
4-(4-Trifluoromethyl-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 4- fluoro-trifluoromethylbenzene. Mp 284.2°C.
4-(4-Chloro-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt
Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 1- chloro-4-fluorobenzene. Mp 246.9-251.6°C.
4-(2,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt
Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 1 ,3- dichloro-4-fluorobenzene. Mp >300°C. 4-(2,5-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt
Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 1 ,4- dichloro-2-fluorobenzene. Mp >300°C.
4-(2,4,5-Trichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt
Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 1 ,2,4,5-tetrachlorobenzene. Mp >300°C.
4-(3-Bromo-4-chloro-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt
Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 3- bromo-4-chloro-1-fluorobenzene. Mp 237-240°C.
4-(2,3,4-Trichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 1 ,2,3,4-tetrachlorobenzene. Mp 258-260°C.
4-(1-Naphthyloxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt
Was prepared according to method B from 4-(2,2,6,6-tetramethyl)-piperidinol and 1- fluoronaphthalene. Mp >300°C.
Method C
(3,4-Dichloro-.phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine hydrochloric acid salt A mixture of 4-amino-2,2,6,6-tetramethylpiperidine (3.4 ml, 20 mmol), potassium tert- butoxide (4.5 g, 40 mmol), 3,4-dichlorobromobenzene (4.97 g, 22 mmol), palladacycle (100 mg, 0.11 mmol) and dioxane (100 ml) was stirred at reflux for 2 h. Water (100 ml) was added and the mixture was extracted with diethyl ether (2 x 50 ml). Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound. Yield 5.56 g, (82 %). Hydrochloric acid in ether (6.5 ml, 3.1 M) was added and the hydrochloric acid salt was precipitated and stirred for 10 min, followed by filtration. Mp >300°C.
(4-Chloro-3-trifluoromethylphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine fumaric acid salt
Was prepared according to method C. Mp 237°C.
(3-Chloro-4-fluorophenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine fumaric acid salt Was prepared according to method C. Mp 269°C. (2-Chloro-5-fluorophenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine fumaric acid salt
Was prepared according to method C. Mp 268°C.
(4-Chloro-3-methoxyphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine fumaric acid salt
Was prepared according to method C. Mp 242-245°C.
(2,4-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine fumaric acid salt
Was prepared according to method C. Mp >250°C (Dec).
(2,5-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine fumaric acid salt
Was prepared according to method C. Mp 241-244°C.
(2,3,5-Dichloro-phenyl)-(2,2,656-tetramethyl-piperidin-4-yl)-amine fumaric acid salt
Was prepared according to method C. Mp 259-261 °C.
(2,3-Dimethoxy-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine hydrochloric acid salt
Was prepared according to method C. Mp 165°C.
(1-Naphthoxy-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine hydrochloric acid salt
Was prepared according to method C. Mp 179-181 °C.
Method D
[4-(3,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidin-1-yl]-acetonitrile hydrochloric acid salt
A mixture of 4-(3,4-dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine (1.22 g, 3.9 mmol), potassium carbonate (6.9 g, 50 mmol), cyanomethylbenzenesulfonate (7.5 ml, 40 mmol) and DMSO (20 ml) was stirred at 70°C for 15 h. Water (100 ml) was added and the mixture was extracted with diethyl ether (2 x 50 ml). Chromatography on silica gel with ethyl acetate : petroleum (1:1) gave the title compound. Hydrochloric acid in ether was added and the hydrochloric acid salt was precipitated and stirred for 10 min, followed by filtration. Yield 0.23 g, (16 %). Mp >200°C (Dec). Method E 4-(4-Chloro-3-trifluoromethyl-phenoxy)-2,2,6,6-tetramethyl-piperidine hydrochloric acid salt A mixture of 4-(4-chloro-3-trifluoromethyl-phenoxy)-1 ,2,2,6,6-pentamethyl-piperidine 5 (1.28 g, 4.26 mmol), toluene (50 ml) and diethylazodicarboxylate (2.0 ml, 12.8 mmol) was heated at 110°C for 8 h. Hydrochloric acid (20 ml, 2 M) was added at reflux for 2 h. The mixture was cooled on ice. The hydrochloric acid salt precipitated and was isolated by filtration. Yield 1.2 g (87%). Mp 222°C.
10 Method F (3,4-Dichloro-phenyl)-methyl-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-amine hydrochloric acid salt A mixture of 4-(3,4-dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine (0.37 g, 1.2 mmol), formic acid (5 ml, 98%) and formaldehyde (5 ml, 37%) was stirred for 4 h at
15 85°C. Aqueous ammonia (25 ml) was added and the mixture was extracted with diethyl ether (2 x 50 ml). Chromatography on silica gel with dichloromethane, methanol and cone ammonia (40:9:1%) gave the title compound. Hydrochloric acid in ether was added and the hydrochloric acid salt was precipitated and stirred for 10 min, followed by filtration. Yield 0.18 g, (43%). Mp >200°C (Dec).
20 Method G (4-Bromo-2,3-fluoro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine hydrochloric acid salt To a mixture of 4-amino-2,2,6,6-tetramethylpiperidine (2.7 ml, 16 mmol) and THF (50
25 ml) was added butyllithium (8.4 ml, 21 mmol). The mixture was stirred at room temperature for 1 h. 1-Bromo-2,3,4-trifluorobenzene (4.0 g, 19 mmol) was added and the mixture was stirred at reflux for 1 h. Aqueous sodium hydroxide (25 ml) was added and the mixture was extracted with diethyl ether (2 x 50 ml). Chromatography on silica gel with dichloromethane, methanol and cone ammonia (90:9:1%) gave the title
30 compound. Hydrochloric acid in ether was added and the hydrochloric acid salt was precipitated and stirred for 10 min, followed by filtration. Yield 0.14 g, (2%). Mp >250°C (Dec).
(4-Chloro-2-fluoro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine hydrochloric 35 acid salt Was prepared according to method G. Mp >160°C (Dec). Method H
(2-Bromo-4-chloro-5-methoxyphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine hydrochloric acid salt
A mixture of (4-chloro-3-methoxyphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine 0.40 g, 1.3 mmol), acetonitrile (10 ml) and NBS (0.23 g, 1.3 mmol) was stirred for 1h at 100°C. Water (25 ml) was added and the mixture was extracted with diethyl ether (2 x 50 ml). Hydrochloric acid in ether was added and the hydrochloric acid salt was precipitated and stirred, followed by filtration. Yield 0.40 g, (75%). Mp >270°C.

Claims

1. A piperidine derivative of the Formula I:
Figure imgf000022_0001
any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, wherein Ra represents hydrogen or alkyl; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; X represents -O-, -S- or -NR0-; wherein R° represents hydrogen, alkyl, -C(=O)Rd or-SO2Rd; wherein Rd represents hydrogen or alkyl; Rb represents an aryl group, which aryl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; each of R2, R2', R3, R3', R5, R5', R6 and R6' independently of each other represents hydrogen or alkyl; with the proviso that at least one of R2, R2', R3, R3', R5, R5', R6 and R6' represents alkyl; and with the proviso that the compound is not 4-(4-hydroxy-phenoxy)-2,2,6,6-tetramethyl-piperidine or 4-(4-methoxy-phenoxy)-2,2,6,6-tetramethyl-piperidine.
2. The chemical compound of claim 1 , wherein Ra represents hydrogen or alkyl.
The chemical compound of claims 1 or 2, wherein Rb represents a phenyl group, which phenyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy.
The chemical compound of claims 1 or 2, wherein Rb represents a phenyl group, which phenyl group is optionally substituted twice with halo.
The chemical compound of any one claims 1-4, wherein X represents -O-.
The chemical compound of any one claims 1-4, wherein X represents -NRC-.
The chemical compound of any one claims 1-6, wherein four of R2, R2', R3, R3', R5, R5', R6 and R6' represent alkyl; and the remaining four of R2, R2', R3, R3', R5, R5', R6 and R6' represent hydrogen.
8. The chemical compound of claim 1 , which is 4-(3,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(4-Chloro-3-trifluoromethyl-phenoxy)-1,2,2,6,6-pentamethyl-piperidine; 4-(4-Chloro-3-fluoro-phenoxy)-1,2,2,6,6-pentamethyl-piperidine; 4-(4-Bromo-3-chlorophenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(3,4-Dichloro-phenoxy)-1 ,2,2,6,6-pentamethyl-piperidine; 4-(3-Chloro-4-fluoro-phenoxy)-1,2,2,6,6-pentamethyl-piperidine; 4-(3-Chloro-4-fluoro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(2-Chloro-5-fluoro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(4-Trifluoromethyl-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(4-Chloro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(2,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(2,5-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(2,4,5-Trichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(3-Bromo-4-chloro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(2,3,4-Trichloro-phenoxy)-2,2,6,6-tetramethyl-piperidine; 4-(1-NaphthyIoxy)-2,2,6,6-tetramethyl-piperidine; (3,4-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (4-Chloro-3-trifluoromethylphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (3-Chloro-4-fluorophenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (2-Chloro-5-fluorophenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (4-Chloro-3-methoxyphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (2,4-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; 5 (2,5-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (2,3,5-Dichloro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (2,3-Dimethoxy-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (1-Naphthoxy-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; [4-(3,4-Dichloro-phenoxy)-2,2,6,6-tetramethyl-piperidin-1-yl]-acetonitrile; 10 4-(4-Chloro-3-trifluoromethyl-phenoxy)-2,2,6,6-tetramethyl-piperidine; (3,4-Dichloro-phenyl)-methyl-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-amine; (4-Bromo-2,3-fluoro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (4-Chloro-2-fluoro-phenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; (2-Bromo-4-chloro-5-methoxyphenyl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine; 15 or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of any one of claims 1-8, or the compound 4-(4-hydroxy-phenoxy)-2,2,6,6-tetramethyl-piperidine or 4-(4-methoxy-phenoxy)-2,2,6,6-tetramethyl-piperidine,
20 any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
10. Use of the chemical compound of any of claims 1-8, or the compound 4-(4-hydroxy-phenoxy)-2,2,6,6-tetramethyI-piperidine or
25 4-(4-methoxy-phenoxy)-2,2,6,6-tetramethyl-piperidine, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament.
11. The use according to claim 10, for the manufacture of a pharmaceutical
30 composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
35 12. The use according to claim 11 , wherein the disease, disorder or condition is mood disorder, depression, atypical depression, depression secondary to pain, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, post-traumatic stress disorder, acute stress disorder, drug addiction, drug abuse, cocaine abuse, nicotine abuse, tobacco abuse, alcohol addiction, alcoholism, pain, chronic pain, inflammatory pain, neuropathic pain, migraine pain, tension-type headache, chronic tension-type headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, post-operative pain, post-mastectomy pain syndrome (PMPS), post- stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically- maintained pain, trigeminal neuralgia, dental pain, myofacial pain, phantom-limb pain, bulimia, premenstrual syndrome, late luteal phase syndrome, post- traumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress incontinence, urge incontinence, nocturnal incontinence, sexual dysfunction, premature ejaculation, erectile difficulty, erectile dysfunction, premature female orgasm, restless leg syndrome, eating disorders, anorexia nervosa, sleep disorders, autism, mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain damage, stroke-induced neuronal damage or Gilles de la Tourettes disease.
13. A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-8, or the compound 4-(4-hydroxy-phenoxy)-2,2,6,6-tetramethyl-piperidine or 4-(4-methoxy-phenoxy)-2,2,6,6-tetramethyl-piperidine, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
PCT/EP2005/052731 2004-06-18 2005-06-14 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors WO2005123679A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2007515944A JP2008502651A (en) 2004-06-18 2005-06-14 Novel alkyl-substituted piperidine derivatives and their use as inhibitors of monoamine neurotransmitter reuptake
EP05761133A EP1761493A2 (en) 2004-06-18 2005-06-14 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA002570075A CA2570075A1 (en) 2004-06-18 2005-06-14 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US11/579,060 US7547788B2 (en) 2004-06-18 2005-06-14 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MXPA06013917A MXPA06013917A (en) 2004-06-18 2005-06-14 Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors.
US12/437,233 US7915419B2 (en) 2004-06-18 2009-05-07 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US12/970,274 US20110086880A1 (en) 2004-06-18 2010-12-16 Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200400961 2004-06-18
DKPA200400961 2004-06-18
US58135904P 2004-06-22 2004-06-22
US60/581,359 2004-06-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/579,060 A-371-Of-International US7547788B2 (en) 2004-06-18 2005-06-14 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US12/437,233 Division US7915419B2 (en) 2004-06-18 2009-05-07 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Publications (2)

Publication Number Publication Date
WO2005123679A2 true WO2005123679A2 (en) 2005-12-29
WO2005123679A3 WO2005123679A3 (en) 2006-03-02

Family

ID=37311739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/052731 WO2005123679A2 (en) 2004-06-18 2005-06-14 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Country Status (9)

Country Link
US (3) US7547788B2 (en)
EP (1) EP1761493A2 (en)
JP (1) JP2008502651A (en)
CN (1) CN1960974A (en)
AR (1) AR050341A1 (en)
CA (1) CA2570075A1 (en)
MX (1) MXPA06013917A (en)
TW (1) TW200604173A (en)
WO (1) WO2005123679A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131524A1 (en) * 2005-06-08 2006-12-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2008025777A1 (en) * 2006-08-30 2008-03-06 Neurosearch A/S Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2009109519A1 (en) * 2008-03-05 2009-09-11 Neurosearch A/S Novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptatke inhibitors
WO2015177193A1 (en) * 2014-05-21 2015-11-26 Solvay Specialty Polymers Usa, Llc Stabilizer compounds
WO2015176978A1 (en) * 2014-05-21 2015-11-26 Solvay Specialty Polymers Usa, Llc Piperidine-based stabilizers and polymers end-capped with the same
EP3048097A1 (en) 2015-01-22 2016-07-27 Evonik Degussa GmbH Method for producing an n-methyl substituted triacetone amine compound
EP3266770A1 (en) 2016-07-07 2018-01-10 Evonik Degussa GmbH Method for producing an n-methyl substituted triacetone amine compound
US10227300B2 (en) 2015-01-22 2019-03-12 Evonik Degussa Gmbh Synthesis of triacetonediamine compounds by reductive amination proceeding from triacetonediamine and derivatives thereof
US10252978B2 (en) 2016-07-07 2019-04-09 Evonik Degussa Gmbh Synthesis of triacetonediamine compounds by reductive amination proceeding from triacetonediamine and derivatives thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123679A2 (en) * 2004-06-18 2005-12-29 Neurosearch A/S Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8546576B2 (en) * 2008-06-06 2013-10-01 Sk Biopharmaceuticals Co., Ltd. 3 or 4-substituted piperidine compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030997A1 (en) 1996-02-22 1997-08-28 Neurosearch A/S Tropane-derivatives, their preparation and use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3684765A (en) * 1970-01-08 1972-08-15 Sankyo Co Stabilization of synthetic polymers
GB1411782A (en) * 1972-02-24 1975-10-29 Wyeth John & Brother Ltd Piperidine derivatives
US3907813A (en) * 1973-09-11 1975-09-23 Janssen Pharmaceutica Nv Stereoisomeric forms of 4-anilino-3-methyl piperidines
US3923992A (en) * 1974-05-23 1975-12-02 Univ Mississippi Analgetic composition and method of use
FR2361880A1 (en) * 1976-04-29 1978-03-17 Science Union & Cie NEW 4-AMINO PIPERIDINES, THEIR PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING
DE3218645A1 (en) * 1982-05-18 1983-11-24 Hoechst Ag, 6230 Frankfurt FLUORANE CONNECTIONS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS COLOR IMAGES IN COPYING SYSTEMS
JPS63206757A (en) * 1987-02-23 1988-08-26 Mitsubishi Paper Mills Ltd Electrophotographic sensitive body
US5019583A (en) * 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US4939161A (en) * 1989-05-12 1990-07-03 Boc, Inc. Analgesic N-aryl-N-[1-substituted-3,5-dimethyl-4-piperidinyl]amides
JP3041823B2 (en) * 1989-09-09 2000-05-15 クラリアント ファイナンス（ビーブイアイ）リミティド Synthetic polyamides and their salts
JPH11348418A (en) * 1998-04-08 1999-12-21 Seiko Epson Corp Recording medium and recording solution
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
WO2002089803A1 (en) * 2001-05-07 2002-11-14 Sankyo Company, Limited Composition for iontophoresis
BR0314821A (en) * 2002-11-01 2005-08-02 Neurosearch As Piperidine derivative, pharmaceutical composition, use of the piperidine derivative, and, method for treating, preventing or alleviating a disease or disorder or condition of a living animal body
WO2005123679A2 (en) * 2004-06-18 2005-12-29 Neurosearch A/S Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030997A1 (en) 1996-02-22 1997-08-28 Neurosearch A/S Tropane-derivatives, their preparation and use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", MAACK PUBLISHING CO.
JAQUES J; COLLET A; WILEN S: "Enantiomers. Racemates, and Resolutions", 1981, JOHN WILEY AND SONS
MORISHIMA Y; FUJITA J; IKEDA T; KAMACHI M, CHEMISTRY LETTERS, 1994, pages 3 557 - 60

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131524A1 (en) * 2005-06-08 2006-12-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2008025777A1 (en) * 2006-08-30 2008-03-06 Neurosearch A/S Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2009109519A1 (en) * 2008-03-05 2009-09-11 Neurosearch A/S Novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptatke inhibitors
CN106458895A (en) * 2014-05-21 2017-02-22 索尔维特殊聚合物美国有限责任公司 Piperidine-based stabilizers and polymers end-capped with the same
WO2015176978A1 (en) * 2014-05-21 2015-11-26 Solvay Specialty Polymers Usa, Llc Piperidine-based stabilizers and polymers end-capped with the same
WO2015177193A1 (en) * 2014-05-21 2015-11-26 Solvay Specialty Polymers Usa, Llc Stabilizer compounds
CN106458895B (en) * 2014-05-21 2020-12-11 索尔维特殊聚合物美国有限责任公司 Piperidine-based stabilizers and polymers capped therewith
US11111358B2 (en) 2014-05-21 2021-09-07 Solvay Specialty Polymers Usa, Llc Stabilizer compounds
US11111215B2 (en) 2014-05-21 2021-09-07 Solvay Specialty Polymers Usa, Llc Piperidine-based stabilizers and polymers end-capped with the same
EP3048097A1 (en) 2015-01-22 2016-07-27 Evonik Degussa GmbH Method for producing an n-methyl substituted triacetone amine compound
US10227300B2 (en) 2015-01-22 2019-03-12 Evonik Degussa Gmbh Synthesis of triacetonediamine compounds by reductive amination proceeding from triacetonediamine and derivatives thereof
EP3266770A1 (en) 2016-07-07 2018-01-10 Evonik Degussa GmbH Method for producing an n-methyl substituted triacetone amine compound
DE102016212379A1 (en) 2016-07-07 2018-01-11 Evonik Degussa Gmbh Process for the preparation of an N-methyl-substituted triacetoneamine compound
US10252978B2 (en) 2016-07-07 2019-04-09 Evonik Degussa Gmbh Synthesis of triacetonediamine compounds by reductive amination proceeding from triacetonediamine and derivatives thereof
US10358420B2 (en) 2016-07-07 2019-07-23 Evonik Degussa Gmbh Process for preparing an N-methyl-substituted triacetonamine compound

Also Published As

Publication number Publication date
CA2570075A1 (en) 2005-12-29
US7547788B2 (en) 2009-06-16
US7915419B2 (en) 2011-03-29
MXPA06013917A (en) 2007-03-07
WO2005123679A3 (en) 2006-03-02
CN1960974A (en) 2007-05-09
US20110086880A1 (en) 2011-04-14
AR050341A1 (en) 2006-10-18
EP1761493A2 (en) 2007-03-14
TW200604173A (en) 2006-02-01
US20070167487A1 (en) 2007-07-19
JP2008502651A (en) 2008-01-31
US20090215820A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
US7915419B2 (en) Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7696350B2 (en) Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7250425B2 (en) 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7560562B2 (en) Piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8410271B2 (en) Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7973082B2 (en) Substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors
US20110053985A1 (en) Novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7638532B2 (en) 3-aryloxy-8-aza-bicyclo[3.2.1]oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20110046179A1 (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20090124663A1 (en) Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20090023772A1 (en) Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors
EP1937261B1 (en) Novel azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8093388B2 (en) 3-aza spiro[5,5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
ZA200502498B (en) Novel pireidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20100298380A1 (en) N-aryl-n-piperidin-4-ylmethyl-amide derivatives and thier use as monoamine neurotransmitter re-uptake inhibitors
EP1896468A1 (en) 3 -aryloxy- 8 -aza-bicyclo [3.2.1.] oct- 6- ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005761133

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007167487

Country of ref document: US

Ref document number: 11579060

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 200580017255.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013917

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2570075

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007515944

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005761133

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11579060

Country of ref document: US